Medical therapies for meningiomas

被引:119
作者
Wen, Patrick Y. [1 ,2 ,3 ]
Quant, Eudocia [1 ,2 ,3 ]
Drappatz, Jan [1 ,2 ,3 ]
Beroukhim, Rameen [1 ,3 ,4 ,5 ,6 ]
Norden, Andrew D. [1 ,2 ,3 ]
机构
[1] Dana Farber Brigham & Womens Canc Ctr, Dept Med Oncol, Ctr Neurooncol, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Neurol, Div Neurooncol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Dept Med, Cambridge, MA USA
[6] Broad Inst, Canc Program, Cambridge, MA USA
关键词
Meningiomas; Chemotherapy; Hormonal therapy; Antiangiogenic therapies; Targeted molecular therapies; EPIDERMAL-GROWTH-FACTOR; PHASE-II TRIAL; FACTOR RECEPTOR; RECURRENT MENINGIOMAS; MALIGNANT MENINGIOMAS; FACTOR/SCATTER FACTOR; MOLECULAR-GENETICS; MITOGENIC SIGNALS; INTERFERON-ALPHA; NATURAL-HISTORY;
D O I
10.1007/s11060-010-0349-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Meningiomas are the most common primary brain tumor in adults. Although the majority of these tumors can be effectively treated with surgery and radiation therapy, an important subset of patients have inoperable tumors, or develop recurrent disease after surgery and radiotherapy, and require some form of medical therapy. There are increasing numbers of studies evaluating various medical therapies but the results remain disappointing. Chemotherapies and hormonal therapies have been generally ineffective, although somatostatin analogues may have therapeutic potential. There is also increasing interest in targeted molecular therapies. Agents inhibiting platelet derived growth factor receptors and epidermal growth factor receptors have shown little efficacy, but molecular agents inhibiting vascular endothelial growth factor receptors appear to have some promise. As with other tumors, advances in the medical therapies for meningiomas will require improved understanding of the molecular pathogenesis of these tumors, more predictive preclinical models, and efficient mechanisms for conducting clinical trials, given the small population of eligible patients.
引用
收藏
页码:365 / 378
页数:14
相关论文
共 158 条
[1]  
Adjei Alex A, 2005, Cancer Chemother Biol Response Modif, V22, P123
[2]   Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas [J].
Andersson, U ;
Guo, D ;
Malmer, B ;
Bergenheim, AT ;
Brännström, T ;
Hedman, H ;
Henriksson, R .
ACTA NEUROPATHOLOGICA, 2004, 108 (02) :135-142
[3]   Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity [J].
Arena, S ;
Barbieri, F ;
Thellung, S ;
Pirani, P ;
Corsaro, A ;
Villa, V ;
Dadati, P ;
Dorcaratto, A ;
Lapertosa, G ;
Ravetti, JL ;
Spaziante, R ;
Schettini, G ;
Florio, T .
JOURNAL OF NEURO-ONCOLOGY, 2004, 66 (1-2) :155-166
[4]   An orthotopic skull base model of malignant meningioma [J].
Baia, Gilson S. ;
Dinca, Eduard B. ;
Ozawa, Tomoko ;
Kimura, Edna T. ;
McDermott, Michael W. ;
James, C. David ;
VandenBerg, Scott R. ;
Lal, Anita .
BRAIN PATHOLOGY, 2008, 18 (02) :172-179
[5]   Endothelins are angiogenic [J].
Bek, EL ;
McMillen, MA .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 36 :S135-S139
[6]   αvβ3 and αvβ5 integrin expression in meningiomas [J].
Bello, L ;
Zhang, JP ;
Nikas, DC ;
Strasser, JF ;
Villani, RM ;
Cheresh, DA ;
Carroll, RS ;
Black, PM .
NEUROSURGERY, 2000, 47 (05) :1185-1195
[7]   Is there an association between meningioma and hormone replacement therapy? [J].
Blitshteyn, Svetlana ;
Crook, Julia E. ;
Jaeckle, Kurt A. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) :279-282
[8]   SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile [J].
Bruns, C ;
Lewis, I ;
Briner, U ;
Meno-Tetang, G ;
Weckbecker, G .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2002, 146 (05) :707-716
[9]   Meningiomas in 2009 Controversies and Future Challenges [J].
Campbell, Belinda A. ;
Jhamb, Ashu ;
Maguire, John A. ;
Toyota, Brian ;
Ma, Roy .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (01) :73-85
[10]   Combining radiation and molecular targeting in cancer therapy [J].
Camphausen, K ;
Tofilon, PJ .
CANCER BIOLOGY & THERAPY, 2004, 3 (03) :247-250